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COMMISSION OF THE EUROPEAN COMMUNITIES 
Brussels, 03.09.f997 
COM(97) 369 fmal 
_  97/0197 (COD) 
Proposal for a _ 
EuROPEAN PARLIAMENT AND COl,INCII,.:.illRECTIVE 
on: the approximation of  provisions lai? down by law, regulation or administrative action  -
relating to the implementati011 of  Good Clinical Practice irt th-e conduct of  cl_inicattrials on 
medicinal prddtH.:ts for hun1an use  --
(presented by the Commission) 
-----'  -
Explanatorv ft!I eniormidum 
1.  .)3ACKGROUND 
· · With  the  introduction  of,  the  first  legi.slation  deaii~g. ~ith  pharmaceuticals,  twin 
principles  of'  protectioo . of public health_  and  free  movement  of p'toducts  were 
enshrined.  Directive  6~/65/EEC on- the  approximation of provisions  laid_ dOwn -by: 
law, regulation or adniinistrative action 'relating to  medicinal  products requires that 
medicinal products must have a marketing authorisati9n prior to being placed _on  the 
market in the European 'community. Further, the criteria upon which. access· to the 
marketplace is  determined - quality,  safety and efficacy - have been clearly set out. . 
Demonstration,·. particulac!y of  the latter two genenilly rely on clinical- trials in human 
subjects  .. 
The standards for the conduct of clinical  trials  have  been developed progressively, 
both  within  the· Eurqpean  Community  and  internationally: These  standards  were 
· c·odified  in  theEuropean Union guidelif!e on Good Clinical Practice (GCP) in  1990 
and  are  follo\ved. il}  clinical  research- by  the.  pharma~euti~al  industry.  W.ith  the 
.  globalisation of the  pharmaceutical  industry;  the  international harmonisation of the· 
·, standards of \\·ere also undertaken - in the fo~m  of the  Internati~nal Conference on 
Harmonisation. 
Since January  1997,  the  internationally.~harmonised ·GCP  is  now incorporated  irito 
clinical. pra.ctice  within  the  Community· by  virtue· of  their inclusion  in  . 'The  rules  . 
· gcfverning medicinal products in,the European Union'  publi_s_hed  by  the Commission 
in  accordance with the annex to Directive 75/3l8/EJ:C on the approximation of the · 
h~vs of Mentber. States relating  to analytical;  pliarmacotoxicological ;and  cliQical 
standards and protocols in  re~pect of the testing of medicinal  products as  a~ended. 
Because  such  guidelines  are. not  binding;-.  a  supportive  legislative  framework  is 
required .. This is to be-achieved using two approaches:  firstly,  by this proposal for a 
Council  Directive reinforcing existing  practice arid  harmonising  procedures for the 
. commencement  of clinical  trials;  secondly,  with :a  delegation . of power· to  the 
Con11nissiort. to adopt a  Directive containing the detailed principles and guidelines on 
GCP.  .  .  __  -~  .  ·  - ·  - · 
- 1-' 2.  SUBSIDIARITY AND PROPORTIONALITY 
All Member States have ·either legislative and/or administrative provisions relating to 
the commencement of a clinical' trial.  However, the requirements. are .not the same 
and given that current .approaches to the demonstration of  clinical safety and efficacy 
(for example, placebo controlled double blirid trials) frequently involve thousands of 
· subjects, the practice has developed of applying the same trial protocol in  multiple 
investigational  sites.  These  'multi-centre'  clinical_  trials,  when  conducted  in  the 
European Union, would frequently take place in more than one Member State. Thus, 
currently, the conduct of  the same trial must comply with d~fferent national provisions 
resulting  in  delays  of up  to ·nine  moiJths  in  the  initiation  of a  clinical  trial  with 
consequential delays for patients  .. 
Therefore this legislative proposition is designed to build on the existing experience of 
the Member  States  ,  ensuring  the  same  level  of patient protection  and  scientific 
stand~rds,  but  with  a  rationalisation  of  the.  documentary  and  administrative 
· ·procedures involved in multi-centre clinical trials.  Additioqally, the proposal includes 
a series of definitions which have been internationally agreed and which codify the 
terms used in the Meml?er States, on the basis of  which clinical trial data generated in 
the European Union is internationally mobile.  · 
It is  important  to  note .that  this  proposal,  based. on . article  1  OOa,  is  in  fact  a 
, -rationalisation  of  legislation  since  overall  the  administrative.  and  bureaucratic 
requirements will be reduced in line with a 'risk-based' approach, thus allowing new 
medicines to be made available to patients in  a timely manner. It is also intended to . 
simplify  the  regulatory  burden  for  small  and  medium  companies  e.g.  start  up 
biotechnology companies, for whom the current complexity of national requirements · 
makes it almost impossible to conduct trials in more than one Member State. 
. 3.  PROTECTION OF THE TRIAL SUBJECT  . 
The accepted basis for· the conduct of clinical trials in humans is founded in the current 
revision of  the DeClaration ofHelsinki and the Council of  Europe draft Convention for 
the  protection of human  rights  and  dignity  of the  human  being with  regard  to  the 
application  of  biology  and  medicine  (The  Convention  on  Human  Rights  and 
Biomedicine). 
· In  practice,  this  means  that  the  clinical  trial  has  been  considered  -by  an  Ethics 
Committee  and  by  the  competent  authority  of the  Member  State.  Further,  .the 
investigator  is  responsible  for  the  personal  safety  and  well-being  of subjects  in  a 
clinical  trial.  In the laws of the Member States, the protection of the trial  subject is 
provided  for  both  through  adoption  of international  conventions  and  ·additional 
legislative provisions.  In accordance with the principle of subsidiarity and .given that 
the protection afforded by the different Member States appears sufficient and does not 
jeopardise  t!Je  internal  market,  harmonisation  is  not . proposed.  'However,  spme 
fundamental principles which are currently applied in all Member States are recalled in 
the proposal.  ·  · 
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·I · For  the  protection  of subjects  in  a  ·clinical  -trial,  1t  .IS ·important  that  complete 
information  is  provided  and  that,  as . necessary,  additional  inforrriation  'may ' be . 
requested; The subjects participation in the clinical trial is confidential and, asthe data 
relating to the_ study may be available:to third· parties such as monitors and regulatory . 
bodies, it should rP.main ·anonymous  .. AU data should· be secured. aga_inst  unauthorised 
.  access. and  confidentiality should be ·observed  at all  times.  This  directi":e  is  without 
__  prejudice to Directive 95/46/EEC on the protection of individuals with regard to th•e 
processing of  perso'nat data and on  the free movement of  such data. 
Prior to enrolment in a Clinical trial; the trial :mbjectshquld.receive easy to understand 
information .  on  the  nature  of the  trial  (P_atient  information)  and  be  afforded  the 
. opportunity to ask and· receive answers to questions.  Consent to participate is  then· 
· confirmed by the 'Informed consent' r~cord, . ·  · - .  -· ·  ·  -..  .  .  . 
Legal texts in  themselves  provide onl; a- framework  within which to work.  Ethics 
ca·nnot be grafted onto a trial- it.must be built in from the outset. Ultimately an ethical 
attitude· must  pervade· the  approach  to  di11ical  investigation,  its  estAblishment  and 
follow through.·  · 
4.  ETHICS CoMM:IT:fEES 
The Treaty on Evrope<m. Union recognise the need to respect the history," culture_ and . · 
traditions of the  peoples  of thee Union.  In  Europe  there  is· a  diversity. of cultural 
traditions.  Equally there is  diversity in  r.eligicus  beliefs.  This  combination has  led  to 
differing expectations and  practices, both legal and  ~thical. Nonetheless,· the Solidarity 
·.of th~! .peoples of the Uni~~ creates a  firm  basis  for  the  construction of the  future 
. Europe  ... 
·-Ethical· principles the~efore reflect the culture,  tradition- and. expectation of peoples .. 
Ethics also reflect the views of  their time, and perfor~e must be adjusted intime. Thus 
· the i.!Xpression .of detailed  ethical  requirements  in  legislative  texts  has  not  been 'the 
J)ractice in the Member States. Rather the s!andards and ·principles to be fOllowed  are.· 
enshrined in legal form.  · 
T~is.  experi(mce . haJ  bee11  followep  in  this  ·-proposaL  Thus,  the. principles  -~( · 
· consultation,  opinions  in  writing.  and  th-::  necessity· of  on-going  submission·  of 
information to _the  independent ethics  committee are set out.  Generally,  each centre 
where  -.~- clinical  trial  is  conducted  sets  up· an  independent  ethics  committee. the 
..  . membership of  which consists of  doctors other than those involved In  the trial,. nurses 
and/or, other healthcare professionals as well  as non medical people such as  lawyers, 
administrator,· and lay people. This c'ominittee acts to screen the clinical trial in  order 
to ensure the protection of  the rights, safety and well-being of  human subjects involved. 
in the trial. By virtue ofthis independent review, public assl;lrance of  that protection· is 
also attained.  ·  '  · 
- 3 -Thl;lsthe following principles have been elaborated:  · 
•  For the same clinical trial,  all Ethics Committees must be supplied with the same 
information;·  .  '  · 
•- The opinion of  the Ethics committee of  the site where the trial actually takes· place 
must be obtained, particularly as it is this committee that will be most familiar with 
the facilities and qualifications of  the investigator. 
However, the administrative· procedures including the scientific documentation to be 
made available in order to obtain an ethical committee opinion do lend themselves to 
rationalisation, at the high standard necessary for the protection of  trial subjects. 
For multi-centre  multi  Member State clinical  trials,  up  to 50  or 60  si~es ·might  be 
involved.  The  co-ordination of ethical  opinions  from  all  of these  sites  can  impose 
difficulties and delays. In a number of  Member States, procedures have already been 
set up  whereby  either  a  national  ethics  committee,  or a  co-ordination  of regional 
cominittees  or the ·ethics  committee  of the  principal  investigator takes  the .lead  in 
giying an  opinion for the trial.  Thereafter, the ethics  committees of each site either 
accepts or rejects the trial for that site. 
This approach has been followed in the proposal - each Member State would establish  .  . 
its own procedure for achieving a 'lead' opinion for a multi-centre multi-Member State 
clinical tr;ial.  Thus instead of  say 50 or 60 separate opinions, there would be an opinion 
per Member State, :with an acceptance or rejection of  the trial by the Ethics Committee -
ofthe investigational site.  · 
5~ . INNOVATIVE ENVIRONMEN.T 
The pharmaceutical industry in Europe is  highly innovatory and contributes to public 
health  by  virtue  of bringing  forth  new  medicines  for  disease  conditions  for  which 
treatment  is  currently_ insufficient  or  not  available.  The  innovative  nature  of the 
industry  relies  on  re~earch,  particularly  clinical  research.  Equally,  the  conduct  of· 
research in Europe contributes to the knowledge base of the performance in  practice 
of  the medicinal product in the European patient, and permits  ~linical investigators to 
work intimately with evolving science.  Therefore it is  important that cliniCal  research 
sh_ould not be inhibited by unnecessary administrative duplication. 
In most Member States there is a requirement to  ei~her notify or receive approval from 
the  competent  authority  before· commencing  a  clinical  trial  in  the  territory  of that 
Member State. In addition to protecting the trial subject, the current experience with 
systems of notifjcation/approval has proven effective and therefore provides the basis 
for this part of the proposal. Thus, a sponsor would notify the competent authority ·Of 
the clinical trial,  the competent authority would  have the opportunity to react but if 
there was no reaction, the trial would be deemed to be' approved. This approval would 
be valid for the duration of  the trial. 
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Major pharmaceutiCal innovations rely, for the demonstration of  safety and efficacy on 
multi-c(mtre clinical trials. Recent publications have illustrated that a base of 2000 to 
. 3000 human subjects would not be exceptional in the development of a  new active  . 
substance.  As such ·  clinical  trials  are conducted in  universities,  hospitals . or ·clinics, · 
none of which would individually. be capable of recruitiug  the required .  nu~ber of 
subjects; up to 50 or 60 centres would be involved in  a single trial. In the European-
'Union these· centres  are  spread  across. more  than  one Member  State.  Initially  the 
possibility for a single procedure for the commencement of  trans-national Clinical trials 
had  b~en copsidered. this would have provided the possibility whereby, at the r~quest 
of the  sponsor,· a  single  application  could  have  been  submitted  to  the  recently 
established European Agency for  the Evaluation of Medicinal Products-.  However, 
·concerns were raised that the experiences of  Good Clinical Practices and the extent of 
co-operation between Member· States in this. area. were thus far insufficient to provide 
a. basis  for  a  Community  procedure .at  this  time.  The  Commission  regrets  that it 
therefore was ·not  poss~ble to propo_se such a' Community dimension in this proposal, 
but would wish to revisit this aspeCt when some experience has been gained., 
.  .  - .  ~  . 
It is important ·that on-going information on clinical trials be available to all competent 
authorities. Thus selected elements of  the initial application,. as well as amendinents to 
the trial along with the  summary notification ofth~·end of  the trial, whether this is due 
to an early interruption of the trial or in lif2e. with the anticipated duration, would be 
· registered  in  a  database,  accessible  only  to  competent. authoritie.s.  Equally,  the · 
I  . 
information to be submitted to Member States prior to commencement of a_  clinical 
trial is to be harmdnised~  ·both in  cqntent .  and format,  thu's  ensuring that all  Member 
States  receive  the  same  information. ·Included  as  part  of this  information  is  the 
necessary  tmdcol6gical  and  phel;rmacological  tests  in  animals  performeq  as  a  pre-· 
determination o.f risk for human health.  · 
The. potential for risk to the environment which may be associated with  inves~igational 
medicinal products contairiing or. consisting of  genetically modified organisms needs' to 
-be  subjected  to  an  environmentaL risk  as~essment similar  to  that  provided  for  by 
Qirective 90/220/EEC on the. deliberate  release  into  the environment of genetically 
modified organisms  .. The Report
1 on the review of  Directive 90/220/EEC is favourable . 
to the 'verticalisation' ·of part B  as  this would allow  for· more effident and  c;ector-
adapted  apprq~che,s. Also, it seems likely in the future that the pharmaceutical sector 
would be a sector where this would be parti~uhirly relevant.  Thus, once ·t'l.ppropriate 
·experience  has _been  gained,.  this  Directive  would  be  reconsidered  with  a  view  to 
verticalising the assessment ~f  part B of  Directive 90/220/EEC..  ·  .  .  .  '  . 
COM(96) 630 final 
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I Currently, trials undertaken in  other Member States are not required to be notified, 
thus  there is  a  gap  in  the informati9n  available  to  competent  authorities· -:  this  is 
particularly _the  case for multi-centre trials.  Given the importance of this jnformation, 
including for the marketing authorisation assessment  process,  the need to exchange 
information  on  clinical  trials  becomes  evident.  Therefore  the  establishment  of a 
database repository capable of  providing access to the above-mentioned data elements 
and accessible to all competent authorities is provided for. 
In the pharmaceutical sector, an electronic network linking the competent authorities 
ofthe Member States, the European Agency for the Evaluation of  Medicinal Products 
and the Cortunission is  being established under the name EudraNet. Within this the 
'exchange of summary information on clinical trials  can readily be achieved  and the 
possibility  for  electronic  transmission  of information  by -spons,ors  could ·also  be 
ex;Jored.  Further,  this  exchange  would  benefit  the  equivalence . of the  evaluation 
process ,conducted in the Member States such that there can be mutual confidence and 
Jrust in the conduct of  clinical trials. 
6.  GOOD MANUFACTURING PRACTICE 
· In Directive  65/65/EE.C,  article  2,  and  in  Article  34  of Directive  75/319/EEC  an 
exemption from chapters II to V of  the Directive 65/65/EEC is provided for 'medicinal 
products intended for resetrch and development trials'.  Thus such medicinal pr0ducts 
do not require a marketing authorisation, and their manufacture h"s not been subjected 
to a manufacturing authorisation, nor do tlie labelling provisions apply. Nonetheless, 
all Member States agreed, at the timt that the Commission Directive 91/356/EEC was 
adopted that the principles of Good Manufacturing Practice should be complied with 
in  the  manufacture  of medicinal  products  intended  for  use  in ·  ciinical  t~ials.  Many · 
Member States have introduced this requirement in their national legislation. 
In order to avoid differing requirements which are particdarly problematic in the case 
of  multi-centre multi-Member State clinical trials, the proposal applies the prii1Ciples of 
Good  Manufacturing  Practice  to.· investigational  medicinal  products,  including  a 
manufacturing authorisation from the competent author~ty  .. 
Equally  tht:  provisions  for  labelling  need  to  be  codified  so  as  to  ensure  that 
investigational  medicinal  products  can  move  ~cross  .national  boundt~ries.  The 
Commission's  working party of Inspectors  had  already  considered these issues,  and . 
had  prepared  a  guideline  (IIV3004/91 'of 22.12.92)  which  recommendud  minimum 
infjrmation for inclusion in the !abel. To support the application of  GMP, the annex to 
the Gui.de for Good Manufacturing Practice is being revised to include an updating of 
·the guideline HI/3004/9.1 and will be available shortly.  .  .  .  .  . 
Because  of the  (somitimes)  .small  quantities  required. f0r  a  clinical  trial,  many 
investigational medicinal products  ar~ mairutactur.ed  in :laboratories· or even  li.ospital 
pharmacies.  The progressive application of the  trai~ing requirements of the 'qualitfed 
person' as set out ·in ·article 23  of  Directive 75/319/EEC would avoid disruption ofthe 
current supplies of  such products and therefore a special derogation ·is provided for. 
- 6-'  '. 
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7.  VERIFICATION OF COMPLIANCE 
. The concept of  GCP serves to emphasise the need for and importance of  a clear paper 
trail of  the clinical trial, from its inception to its completi6n and analysis. Implicit in the 
requirement that clinical trials meet the standard of GCP is the need for audit of  the , 
study.  Audit may be carried out by an independent internal unit of the  ~ponsor or by 
external contractors. An audit certificate should result.  - . 
Inspection by therelevant competent authority is an officially conduetyd audit.  Thus 
the adherence to the standc~rd can be assured.  Some Mentber States have legislative 
provisions  empowering  inspection. of clinical  trial  sites  and/or  sponsors  and/or 
individual patient files.  The abs~nce of  a Community mechB:nism of mutual recognition 
of  inspections done by the Member States may cause difficulties in·the acceptability of 
studies carried out in other  .Member States.· · 
. The  international  acc~ptability ·  ~f clinical · trials·  conducted  in  the  Community, 
particularly  by  authorities ·outside  the European Community,  requires  a  legislative 
underpinning of  the compliance of  clinical trials with the standard of  GCP. 
Further, in· order to achieve optimum protection of health,  the resources allocated to 
pharmaceutical  research should  not'· be  squandered  on  obsolete  or  repetitive  tests 
whether  within  the  (:ommunity . or  in  third ·countries.  Therefore,  the  international 
harmonisation of technical  requirements for the  development' of medicinal  products 
should  continue  to  be  pursued.  International  fora,  including . the  International 
"Conference  on  Harmonisation,  allow  for  the  scientific  establishment  of standards 
which can preverit duplication; 
'Thus the proposal provides for verification. of  compliance with GCP on beh~lf of the . 
Community by inspectors appointed by Member· States.· The possibility for inspection 
· · of  trials done outside the Community, the results of  which are submitted as part ofthe 
marketing authorisation application is  also  provided for as is  a requirement on those 
su~ject to inspection to allow inspection. 
The need to share knowledg~ and experience, and to build' a system for inspection is 
evident.  The establishment of common criteria ,for  conducting .inspection in  order to 
ensure  mutual  recognition  between  Member  States, .the 'inspection  procedures  for 
multi.,centre multi-national studies, the qualification of insp'ectors and the elaboration 
. of  inspection_ reports are practical aspects which would be elaborated in guidelines. As 
it  would. not  he  practicable or an  effective  use of  resourq:~s to  inspect  every  trial, 
·inspection of quality  systems  would  be  developed.  Equally,  the  inspection  report 
indicating the level of  compliance with  GCPfo~lowing inspection would need to be set 
out.· 
- 7 -. 8.  PHARMACOVIGILANCE 
It is  clear that  the  same · standards  of monitoring  the  safety  in  use  of . medicinal 
products should be used for investigational medicinal products. Thus the provisions for 
pharmacovigilance are extended to include investigational medicin~l products: 
·In the  exercise  on c()dification  of the  Community  legislation  relating  to  medicinal 
products for  human use,  the procedures for  reporting  pharmacovigilance  are  being 
rationalised. The updated procedures for reporting have thus been incorporated 'in this 
proposaL 
9.  INTERNATIONAL HARMONISATION 
A process of  technical harmonisation: of  technical requirements for pharmaceutical has 
been on-=going for the last number of  years.  This is called International Conference on 
Harmonisation  (ICH).  Within  ICH,  a  Good  Clinical  Practice  guideline  has ·been 
elaborated on the .basis of  the European guideline of 1990  . 
. In  order. to  maintain  international  consistency,  the  definitions  of ICH  as  well  as 
procedures where relevant have been retained in the proposaL The only exceptions are . 
in the terminology for medicinal products (in USA the word 'drug' is frequently used) 
and  in the definition of Independent Ethics Committee where the description of the 
membership  reflect~  European  expressions  rather  than  international  ones  i.e. 
"healthcare  medical/scientific  professionals  and  non-meqicali(non scientific) 
members". 
The  need  to  establish  international  harmonisation  of inspection  and  assurance  of 
compliance with GCP, with the possibility of mutual recognition of  inspections, is also 
recogni'sed and needs to be addressed. 
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.  Proposal for a 
EUROPEAN PARLIAMENT AND COUNCIL DIRECTIVE 
of  .................  ,.~,: 
.  on the approximation of  provisions laid down by law,  regulati~n or administrative··~ctio~ 
· relating to the implementation of  Good Clinical Practice in the conduct of  clinical trials on 
·  .  _  •  mediciQal products for human use  ·  · 
'  .  '  .  . 
. THE  EUROPEAN  PARLIAMENT  AND  THE  COUNCIL  OF  THE  EUROPEAN 
UNION, 
Having  regard  to the Treaty  establishing  the European  Community,  and  in  particular 
Article 1  OOa thereof,  · 
Having regard to the proposal from the Commission,  · 
- .  .  . 
.  .  - .  .  . 
Having regard to the opinion of  the Eco~omic  and Social Committee, 
-
·Acting in accordance with the procedure laid down in Article 189b of  the_ Treaty, 
Whereas  Directive  65/65/EEC
2  requires  that  applications  for  authorisation  to  place  a 
medicinal. produCt  on . the  marke~  should .  be  accompanied  by  a'  dossier  containing 
particulars and documents relating to .  the results of tests and clinical trials carried O!Jt  on 
the produCt; whereas Directive 75/318/EEC 
3 lays down uniform rules on the_~ompihition 
of  dossiers including their presentation;  · 
Whereas the· accepted basis for the conduct of clinical trials in humans is  founded in the 
current revision of  the Declaration of  Helsinki and .the Council of-Europe Convention for 
the  protection 'of human  rights  and  dignity  of the  human  being' with  regard  to  the 
application of biology and medicine; whereas; the trial subject's protection is safeguarded 
thro~gh risk  assessment  based  on  to~icologic.al experiments ·prior.· to any  clinical  trial,. 
screeqing by ethics committees; Member States authorities and the protection of personal 
d~~  '  .  .  '  ' 
..J  · . Whereas,  in  order to achieve optimum protection·  of .health,  the  resources .allocated  to 
pharmaceutical research must not be squandered on obsolete or repetitive tests whether 
within the  Coffimunity or in  third  countries;  whereas,  the  harmonisation  of techflical 
requirements  for  the  development  of medicinal  products  should  therefore  be pursued 
through the appropriate fora, including the International Conference ori Harmonisation,-· 
2 
OJ No L22,  9.2.65, p.l 
3  OJ No Ll47, 9.6.75, p.l 
-9,. Whereas, for multi-centre clinical trials conducted in  more than one Member State, with 
many  investigational  sites involved,  a  delay  in  the  commencement  of the  trial  may  be 
caused by the multiplicity  and  diversity of procedures  for  obtaining  opinions  of ethics 
committees; whereas, for such trials,  a single opinion for each Member State concerned 
reduces delays without jeopardising the well-being of the people participating in. the trial 
with the possibility of  rejecting it in specific sites if  facilities are not appropriate; 
Whereas information both on the commencement and on the termination of a clinical trial 
should be available  to  the  Member  States  where  the  trial  takes  place,  and  relevant 
information on clinical trials should be exchanged between Member States; 
< 
Whereas  the  standards  of  Good  Manufacturing  Practice·  should  be  applied  to 
investigational  medicinal  products;  where~s  special  provisions  for  the  labelling  of 
investigational medicinal products should be set' out; 
Whereas verification of compliance with the standards of Good Clinical Practice and the 
need to subject data,  information and  documents to inspection in  order to confirm that 
they have Leen properly generated, recorded and reporteci,  is essential in order to justify 
. the involvement of human subjects in clinical trials; whereas the person  participati~g in a 
trial should be made aware of arid consent to the scrutiny of pers'Jnal information during 
inspec1ion by  competent authorities and properly authorised persons,  provided that such 
personal information is treated as strictly confidential and is not made publicly available; 
Whereas  this  Directive is  without  prejudice  to  Directive  95/46/EEC  of the  European 
Parliament and of the Council of 24  October 1995  on the protection of individuals with 
.  4  . 
regard to the processing of  personal data and on the free mbvement of  such data . 
Whereas it is  also  necessary to make provisions for the monitoring of adverse reactions 
occurring in clinical trials using Community surveillance (pharmacovigilance) procedures 
in  order  to  ensure  the  immediate  cessation  of any  clinical  trial  m  which  there  1s 
. unacceptable level of  risk; 
Whereas the conduct of clinical trials must regularly be adapted to scientific and technical 
progress in order to ensure optimum protection ofthe trial subject; whereas it is therefore 
necessary  to  introduce  a  rapid  procedur.;  for  adapting  to  technical  progress  the 
requirements regarding the conduct of clinical  trials,  whilst ensuring close co-operation 
between the Commission and. the Member States within a 'Committee for the Adaptation 
to-Technical Progress of  the Directives on the Removal of Technical Barriers to Trade in 
the Medicinal Products Sector'; 
HAVE ADOPTED THIS DIRECTIVE:· 
4 
OJ No L281, 23.11.95, p.31 
- 10-.  ....-,  . 
·. _.  CHAPTER! 
, .. 
Scope and definitions 
Article 1· 
'  .  .  '  '  .  .  .  .  . 
1.  This Directive.deals with clini~al trials  inclu~ing multi-centre trials on human subjects. 
involving  med~cinal ·products  as  defined  m  Article  1  of Directive  65/65/EEC  but 
exCludesnon-interventional clinical trials. 
2.  Good Clinical Practice (GCP) is an international ethical and. scientific quality standarq. 
for designing; conducting, recording and reporting trials that involve the participation 
of human subjects.  Compliance with this  standard provides public  assuranc~ that the 
.rights,  safety  a·nd  well-being  of trial  subjects_  are  protected,  consistent  with  the. 
principles  that have their origin in the Declaration of Helsin~i ·  ( 1964  ),'  and  that  the 
clinical trial data are credible. 
3.  The principles and guidelines of  Good Clinical Practi~e shall be adopted in the form of 
a  directive  addressed to the -Member. States,  in  .accordance with. the procedure laid 
down in Article 2c of Council Directive 75/318/EEC. Detailed  g~idelines in  line with 
those principles shall be published by. the Commission and revised  ~s necessary to take 
account oftechnical and scientific progress.  .  . 
. · 4.  All clinical tri~ls, including bioavailabilrty and bioequivalence studies shall be designed,  · 
conducted and reported iri accorpance with the standard of  Good Clinical Practice. 
Article 2 
For the purposes of  this Directive the following definitions shall.apply: 
M  '  0  ~  • 
Adverse Event:  Any  untoward  medical  occurrence in  a  patient  or clinical  investigation 
subject administered  a  medicinal  product and  which does  not  necessarily  have  a  causal 
relationship with this treatment. .  '  .  ·  ·  . 
Adverse Reaction: All  noxious and unintended responses to an  investigational medicinal 
product related to ~my dose. ·  · 
Clinical lhal: Any  investigation  in  hu~ari subjects  intended  t'o  disco~er or verify  the. 
clinical,  pharmacological  and/or  other· pharmacodyriamic  effect-s  of an  investigational -
medicinal  product(s),  and/or' to ideritify  any  adver'se  reactions  tq  an  investigational· 
me9ic;:inal  product(s), .and/or to .study absorption, distribution,  metab9lisin,  anq  excretion 
of  an investigational.prqduct(s) :V.:ith the object of  ascertaining i~s safety' and/or efficacy.  · 
•  1  ,  •·  •  •'  •  •  '  ~  •  •,  •  •  ,  '  •  •'  t  .  ·  ;  '  :.  '  '  •  '  ,  I  ' 
This  include~ Clinical. tfials. do:rie  In  eitherco'ne '·site  0~ :n1ultiple site's,'  wheth~r :in  one 
Member State or in ore than ~~e Meinber State; ·but  .ex~I~des'~on-lntehtentiona:I trials ... ·  · 
'  ' 
'  .. 
'  '  ~·  '  '  •'  I  ·' '• •,  '  ·.  · ...  _;  ·-. 
.  .  '  ~  . 
f  ' 
-.{('- . 
\ Ethics Committee: An independent body constituted of healthcare professionals and non-
medical members, whose responsibility it is  to ensure the protection of the rights,  safety 
and well-being of human subjects involved in a trial and to provide public assurance of 
that protection, by,  among other things, expressing an  opinion on,  the trial protocol, the. 
· suitability of the investigator(s),  facilities,  and  the methods and  material  to be used  in 
ob_taining and documenting informed consent of  the trial subjects.  > 
Inspection:  The  act  by  a  competent  authority  of conducting  an  official  review  of · 
documents, facilities, records, arrangements for quality assurance, and any other resources 
that are deemed by the competent authority to be related to the clini(fal trial and that may 
be located at the site of the trial, at the sponsor's and/or contract research organisation's 
facilities, or at other establishments deemed appropriate by the competent authority. 
Investigational  medicinal produCt:  A  pharmace.utical  form  of an  active  substance. or 
placebo being tested or used as- a reference in a clinical trial,  including a product with a· 
marketing  authorisation  when  used  or assembled  (formulated  or packaged)  in  a  way 
different from the authorised form,  or when used for an unauthorised indication, or when 
used to gain further information about an authorised use. 
Investigator:  A 'person responsible for the conduct of the clinical trial  at a trial site.  If a 
trial is conducted by a team of individuals at a trial site, the investigator is the responsible 
lea.der of  the team and may be called the principal investigator.  _ 
Investigator's  Brochure:  A  compilation  of the  clinical  and  non  clinical  data  on  the 
investigational  medicinal  product(s) which is  relevant to the study of the investigational· 
·medicinal product(s) in human subjects. 
.  . 
Multi centre Trial:  A clinical trial conducted according to a single protocol but at more 
than one site, and therefore, carried out 6y more than one investigator. 
Trial sites may be located in a single Member State, in a number of  Member States and/or 
in Member States and third countries.  · 
Non-ii1terventional trial:  A dinical_trial where the selection ofsubjects or the attribution 
of  medicinal products or the examinations carried out or medical and biological follow-up 
of  subjects falls within current medical practice.· 
Protocol:  A  document that _describes  the .objective(s),  design,  methodology,  statistical 
con_siderations,  and  organisation  .of  a  trial.  The  term  protocol  refers  to  protocol, 
successive versions of  the protocol and protocol amendments. 
Serious Adverse Event or Serious Adverse Reaction:  Any  untoward medical  occurrence 
that  at  any  dose  results  in  death,  is  life-threatening,  requires ·(non-elective)  inpatient 
hospitalisation  or  prolongation  of  existing  hospitalisation,  results  in  persistent  or 
significant disability/incapacity; or is a congenital anomaly/birth defect. 
Sponsor:  An  individual,  company,  institution,  or organisation which  takes responsibility 
for the initiation, management, and/or financing of  a clinical trial.· · - -- /-
Subject:  An 'individual  w,ho  participates in a  clinical  trial,  either  as  a  recipient  of the 
investigational medicinal product or as a control. - -
Unexpected Adverse Reaction:_ An adverse reaction- not mentioned in  the  ~nvestigator's 
·brochure or in the summary of  product characteristics, if any.  · 
CID\PTERII 
Protection of trial subjects 
.Article'3 
1.  This  Directive  is  without  prejudice  to  the  measures  laid  down  in- Member  States 
~onc¢ming the protectio~ oftrial subjects. 
2.  A  clinical  trial -may- only  be _  undertaken  if the  risks  to  the  subject- are  not 
disproportionate tci  the potential-benefits of the medicinal  research. _The  right of the 
subject  to  physic~l and  inental  integrity  shall  be  respected,  as  Well as  the right  to _ 
privacy/ 
.  .  . 
3.  The -medical  care given to, and medical decisions made on behalf of,  subjects shall-be 
the  responsibility  of, .an  appropriately. qualified  healthcare  practitioner  or when 
appropriate, of  a qualified dentist. 
4.  The trial subjec! sh~ll be provided with a contact p~int, independent of  the ·investigate~-
_.tea~, where further information· may be obtain~d.  .  ·  · 
· _}:thics Con1mittee  opinio~ _ 
Article 4 
1.  The function and re~ponsibility of  an ethics committee shall be to safeguard the rights, 
. safety and well-being of  all trial subjects.  ·  ( 
In preparing its opinion, the_ ethics committee shall consider, at least,  the relevance of 
the trial and the trial design, the protocol, the suitabiiity of  the investigator, supporting 
staff, and available facilities; the adequacy and >completen~ss of  the- written information 
-to·  be  given  to  th~  subjects,_  their. relatives,.  gu~rdians  and,  if  ne~essary,  legal 
representatives  and  by  wh_ich~  cop  sent_-.  is  .. to·-- be_- obtained;  . provisiort  __  for -
compensation/treatment-in the case of  inju~y or' de~th or" a subject if  attrib~tabl~  'to. a 
-clinical tdal, and any  insur~nce -or indemnity. to. H>vet  the  lip.~ility of the investigator  -
. ·and spo'nsor;  the extent .to  ~hich inve'stigators.:apd; ~ubjects lllay  be  rewarde_d  or 
compensated for participation -in the triaL_.- - . _  , , _  , _  . .  .  , .  _  · -
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l,  .' 2.  The  op1m~n  of  an  ethics  committee •  shall  be  delivered  before  a  clinical  trial 
commences. 
3.  In  order  to  apply  for  an  op1mon  of an.  ethics  committee,  an  application  with 
documentation shall be.submitted. The written opinion of  the ethics committee shall be 
given to the applicant, in writing, within 30 days of  receipt of  a valid app~ication. 
4.  Within that period,  the ethics committee may  send  a  single  request for  information 
supplementary to that already supplied. In this case the period shall be extended by a 
further 30 days. 
Article 5  . 
1.  Member States shall establish a  proced~1re by which a single ethics committee opinion 
can be achieved for that Member. State. For multi-centre  clinical trials conducted in 
more than one Member State,  tl~is procedure shall provide for the single opinion for 
that Member State. 
2.  Member States may;· in addition, provide for an opinion of  the ethics committee for 
each site on the facilities and capabilities ofthat site in relation to the proposed clinical 
trial. Within 15 days of  receipt of  the opinion provided for in paragraph 1, the ethics 
cornmittee for the site shall, by issuing an opinion, either accept or reject the conduct 
of  the trial in that site. 
Article 6. 
The Commission, in consultation with the Member States and interested parties, shall 
draw  up  detailed  guidance  on  the- application  format -and  documentation  to  be 
submitted in  an application for an ethical committee opinion,  and on the appropriate 
. safeguards for the protection of personal data, in particular regarding the information 
that is given to trial subjects. 
CHAPTER III 
Commencement of a clinical trial 
Article 7 
1.  Before cominen~ing  a clinical trial,  an application shall be submitted by the sponsor 
.. to the Member States where the trial will take place. 
2.  :Member  States shall  ~uthorise  sp~onsots to  commence clinical  trials .once the .ethics 
committee has issued a favourable opinion.- Member States may however decide .that 
certain clinical trials will be subject to paragraph 3. 
- 14-/3.  In the case of clinical trials not  covere~ by  the provisions  of paragraph 2, ·Member 
States shall authorise a sponsor to commence Clinical trials at the end of  a period of  30 
days after receipt of  a  val~d application unless_ reasoned grounds for non-acceptance 
have been notified within this time period.  ·  · 
Within 3  0 days of receipt of the said grounds for non--acceptance,  the sponsor  ~ay 
. amend  on one occasion only the  applicati9n  in  order to .  take  due  account" of the 
grounds set_ out in the notification. If the· sponsor does not amend the application as 
provided for, ,the application is deemed to have been rejected~ . _  · 
4.  Amendments  to  the . protocol- shail  be  notified  to  the- Member- Stat~s.  These 
amendments shall· be deemed to be  ac~epted  -unless the competent authority notifies 
·grounds for non:-acceptance within 30 days.  ,  ·  ·  · 
'  '  ' 
In cases where- grounds -for non-acceptance are· raised, -the  procedur~  ·in, paragraph 3 
shall be followed.  - ·  ·  . 
5.  Notwithstanding paragraph 4,  provisional urgent safety measures may be taken ·by the 
sponsor in <;>rder to eliminate an immediate hazard to trial subjects. -
6.  Within 90 days ofth~ end of  a clinical trial the- sponsor shall notify the Member States 
that the clirucal trial is ·ended.  This period shall. be reduced to  15  days in the case of 
··early termination of  the trial. 
7.  The  Commission  shall,  in- consultation with the .  Member  States,  draw  up  detailed . 
·guidance on the format and contents for applications as well. as the docnmentation to 
be submitted in relation to-the quality and manufacttfre of  the investigational medicinal 
product, any toxicological and pharmacological tests,  •protoc9l and clinical information 
on  the  investigational -medicinal  product  including  the  investiga~ot's  brochure,  m 
addition to the content of  the notificatipn of  the· end of  the clinical trial. 
Exchange of information 
Article 8 
1.  Extracts from the initial application, amendments as appropriate and the notification at 
·the end-of the clinical trial shall be entered by' the Member States in who·se territory ,the 
trial- takes  place  into  a  database  accessible. only  to  Member States,· the  European 
Agency for the Evaluation ofMedieinal Products and.the Commission,  · 
2.  'At the request of any Member State or the ·commission, the :competent authority to -
whom -the  trial was  notified  shall  supply  all  appropriate information concerning that _ 
clinical trial. 
- 15 -
•  I 
,.-3.  In the case of multi-centre clinical trials  conducted in  more than one Member State 
where there are differences between the Member States, the Commission may request 
the Member States concerned to establish the reasons for the difference which shall be 
considered by all Member States. 
4.  The  Commission,  in  consultation with the  Member  Stat_es,  shall  draw  up  detailed 
guidance on the relevant data to be included in this database as well as methods for th~ 
electronic communication of  the data.  • 
Article 9 
1.  Where the conditions of the application cease to be  met  or in  the  event that new 
information raising doubts as to safety or science becomes available, the Member State 
may suspend or prohibit the trial.  It shall forthwith inform the other Mem~er States 
and the Commission thereof. 
The Member State shall inform the other Member States and the Commission of  the 
decisions taken and the reasons for those decisions. 
2.  Where  a Member State is  of the opinion that the sponsor or the investigator is no 
longer fulfilling their obligations laid~  down, it shall forthwith infortp the other Member 
States and the Commission,  stating the reasons in  detail and indicating the course of 
action. 
The Member State shall forthwith inform the Commission of the commencement. of 
any infringement proceedings. 
- CHAPTERIV 
Manufacture, import and labelling of investigational medicinal products 
. Article 10 
1:  Member States shall take all appropriate measures to ensure that the manufacture and 
import of investigational medicinal products is subject to the authorisation referred to 
in Article 16 of  Council Directive 75/319/EEC
5
: 
2.  Chapters IV and V of Directive 75/319/EEC shall  apply to investigational medicinal 
products. 
5 
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3.  A person engaging in the activities of  the person referred to in Article 21  of Directive-
75/319/EEC in a Member State as regards investigational  medicinal  products at the 
time when this Directive i.s -brought into force iri that State but-without complying with 
the  provisions  of Article  23 and  24  of Directive  7-5/319/EEC  shall  be  eligible  to 
continue to engage in those activities for the purpose of  manufacture ofiiwestigational 
medicinal products in the Member State concerned. 
Article 11 
- For investigational medicinal products, _the  particulars to  appea~ in,  at least, the na}ional 
language(  s) on the outer packaging of  investigational medicinal products or where_ there is 
no outer packaging, on the immediate packaging shall be published by the Commission in· 
the Good Manufacturing Practice  guideline on- investigational medicinal- products to be 
adopted in accordance with Article  19aofi~irective 75/319/EEC. 
CHAPTER V 
Compliance_ 
-Article 12 
1.  ·Compliance with the provisions of  Go~d  Clinical Practice sh~ll be v.erified on behalf of 
the  Community -- by  inspection  at_  relevant  sites,  -including . the  trial  site  arid -
manufacturing site, at any laboratory'used in the trial and/or at-the sponso,r's pre.mises, 
by inspectors appointed by Member States.  - -
2.  Following_ inspection, - an  inspectipn  report  shall  be  prepared  which  shall  be made 
available,  upon request, to the  sponsor,_ any  other Member  State  or the European 
Agency for the Evaiuation: of  Medicinal Products  .. ·  - -
3:  Where there are differences between Member States as  to whether the provisions of 
this Directive have been complied with~ the Commission may request a new inspection.-
The co-ordination of  such inspections shall be undertaken by the European Agency for 
·._the Evaluation of  Medicinal Products.  · 
- .  .  .  , 
4.  Subject to any arrangements which may have been concludea b~twee~ the Community 
arid third countries, the C9mmission may,  upon receipt of a reasoned request from  a -
Member  State  or on  its  own  initiative,  require  that  the  trial  site  ,  and/or at the 
sponsor's premises and/or the manufacturer established in a third country submit to art  -
inspection:  The inspection  shall  be  ~ndertaken by  appropriately  qualified  inspectors· 
from the Community.  - ·  - -
5.  The.  Commission,  in consultation with the Member States,  the Europ·ean Agency for 
the Evaluation of Medicinal  Products and  interest'ed  parties,  shall  draw  up  detailed 
- guidelines onthe documentation, archiving, appropriate qualification ofinspectors and 
inspection procedures for the demonstration of  compliance with this Dir_ective. 
- 17 - -CHAPTER VI 
Clinical safety reporting 
Article 13 
1.  The investigator shall  report all  serious  adverse  events  immediately  to the sponsor 
except for those serious adverse events that the protocol or investigator's brochure 
identifies as not requiring immediate reporting. The immediate report shall be followed 
by  detailed,  written  reports.  The  iinmediate  and  follow:up  reports  shall  identify 
subjects by unique code numbers assigned to the trial subjects. 
2.  Adverse events and/or laboratory abnormalities identified in the protocol as critical to 
safety evaluations shall be reported to the ethics committee and the sponsor according 
to the rep()rting requirements and within the time periods specified in the protocol. 
3.  For reported deaths, the investigator shall supply the sponsor and the ethics committee 
with any additional requested information. 
'  4.  The sponsor shall  ensure that all  relevant information  about fatal  or life-threatening 
unexpected adverse reactions are recorded  and  reported as  soon as  possible to the 
Member State in whose territory'the reaction occurred, but in any case no later than 7 
days· after  first  knowledge by the  sponsor that  a  case  qualifies.  All  other  serious 
adverse -reactions that are  not fatal  or life-threatening  shall  be reported  as  soon as 
possible but no later than 15 days. The sponsor shall also inform all investigators. 
5, -In addition, the sponsor shall maintain detailed records of  all  suspected adverse events 
which are reported to him by the investigator(s). These records shall be subn1itted to 
the Member States in whose territory the clinicftl trial is being conducted. 
6.  At least every twelve months  d_uring  the clinical  trial,  the sponsor .shall  provide the 
-Member States in whose territory the clinical trial is being conducted -with a line listing 
of  all suspected serious_adverse reac.ti'Jns  w~ich have occurred in the whole study and 
a summary overview of  the subjects' safety in the trial. 
7.  Each  Member  State_ shall  ensure  that  all suspected  serious  unexpected  adverse 
reactions occurring within their territory to an investigational medicinal product which 
are brought to their attention are recorded and reported immediately to·  the European 
Agency for the Evaluation of Medicinal Products,  and  in  no  case later than  15  days 
following the receipt ofthe information .. 
The European  Agency  for  the  Evaluation  of Medicinal  Products  shall  inform  the 
competent authorities of  the Member States. 
~ 18-S.  The  Commission 'in  consultation ·with the  European Agency  for  the- Evaluation  of 
Medi~inal Products, Member States, and interested parties, shall draw up guidance on 
the collection, verification and presenia~ion of  adverse event/reaction reports  .. 
CHAPTER VII 
General provisions 
Article 14 
This Directive is without prejudice to the ·general civil and criminal liability of  the-sponsor. 
or  the  investi~ator.  ·  ·  ·  ·  ·  .  . 
. Unless ~·:[ember States have established· precis~. conditions.for exceptional Circumstances, 
medicinal products _used in clinical trials  !i~all not be· sold. Member States shall inform the 
Commission ofsuch  c~.nditions  .. · 
Article.15 
Any amendment which may be necessary to update  the provisions of  this Directive.to take 
· account  of scie~tific ·and.  t~chnical· progress  shall  be  adopted  in  accordance  with  the 
. provisions of  Article 2c cifDirective 75/318/EEC. 
-Article 16 
.  Member States shall take all appropriate measures to comply with this Directive before 1  . 
.January 1999. Thf.y shall forthwith i11form the Commission thereof 
When Member  States  adopt  these  provisions; these  shall  :COJitain  J:l.  reference  to  this 
Direct~  ve  Or  shall  be  accompanied  by . such  reference  at  the  time  of their  offi:ial 
publication. The procedure for such reference shall be adopted by Member States. 
.  . 
Member States shall communicate to the  Commission th.e text o(  the provisions· of  national 
. .'  law which they adopt in .th~ field governec(by this Directive: 
·, 
This.Directive Is addressed to the Member States. 
Done at XXXX, 
For :the European Parliamen{ 
The President 
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F01" the Council 
The President . FINANCIAL STATEMENT 
1  1iTLE OF OPERATION: 
Proposal for a European Parliament and Council Directive on the approximation of  ' 
provisions laid down by law, regulation or administrative action relating to the· 
implementation of Good Clinical Practice in the conduct of clinical trials on medicinal 
- products for human use  . 
· .  2  BUDGET HEADING INVOLVED: 
B-5 3000 
3  LEGAL BASIS: 
Article lOOa of the Treaty establishing the European Community . 
. 4  DESCRIPTION OF OPERATION 
4.1  General objective:  . 
To contribute to achieving the objectives laid down by the Treaty: 
•  ensuring a high  -'level of human health protection particularly for human 
subjects in clinical trials for new medicinal products; 
•  harmonisation of the Member States' requirements in order to avoid 
duplicatiort· of effort and  was~  of  resource. 
· 4.2  Period covered aild,arrangements for renewal: 
Aft~r the adoption 9f the Directive, the Commission would ·have a delegation of 
power to introduce a Commission Directive on Good Clinical Practice  · 
(technical standards). This could be foreseen for 1999. 
5 CLASSIF1CATION OF EXPENDITURE OR REVENUE 
5.1  CompulSory/Non-compulsory expenditure 
Some expert working parties (see 7 .1) - non-compulsory expenqiture 
5.2  Differentiated/Non-differentiated appropriations 
Differentiated appropriation (BS-3000) 
5.3  ·Type of revenue involved: 
There are no receipts following this action. 
6TYPE OF EXPENDITURE OR REVENUE 
Technical work directly linked to the preparation of the Commission Directive through 
the Regulatory Committee procedure (A). 
Technical work in the development of guidelines - working parties of experts from 
. Member States (B). 
lo · '·. 
· 7FlNANOALIMPACf 
.  .  .  .  . 
· 7.1 .  ·  · Method of calculating total cost of operation (relation between 
individual and total costs):· 
. The exJ)eCted. cost could be estimated on the basis ofnumber of  ~eetings: 
(a) Preparation oftPe proposal: -... ·  ·  ·  · ,  ·  ·  · 
· •  expert working parties (2 meetings in 1997, ~din  199~); · 
• 'consultation of the Pharmaceutical Committee (during a-regular meeting). 
(  .  .  .  .  .  .  . 
(b) Action following adoption of the proposal:  ~  ·  ·  ·  ·  · 
•  Regulatory Committee fot adoption of the Commission Directive (1  meeting in 
: 1999); 
•  expert working groups (on average,-2 meetings per annum) 
7.2  Itemised breakdown of cost 
Commit~ent  appropriations Ecu·  million . 
(at current prices) 
Break- 1997  1998·.  ·1999  2000  2001 .  '2002 
down 
a  50,000  50,000 
b  75,000  . 50,000  50,000- . '50,000· 
Total  50,000  '50,000.  '  75,000  50,000  4 •  50,000  . 50,000 
.  .  . . 
. 7.3 Operational expenditure for studies,.  experts etc.: inclu~ed: in Part  .B  of_,. the 
·  budget  . 
Publication  of guidelines  supporting  the .  oper:ation  and  implementation  of the 
directive which would be.included in the 'Rules· governing medicinal products in the 
·European Union' as part of  volume 3. Therefore there is no additional cost (already: 
covered by the annual budget for publications): 
·' 
2\ 
Total 
' 
100,000 
225,000 
325,000 7.4  Schedule of commitment and payment appropriations 
ECU million 
1997  1998  1999  2000  2001  2002 and  Total 
/ 
subs. yrs 
Commitment  50,000  50,000  75,000  50,000  50,000  50,000  325,000 
appropriations 
Payment  -
I 
appropriations  • 
1997  50,000  50,000 
1998  50,000  50,000 
195i9 
I  75,000 .  75,000 
2000  50,000  50_!_000 
2001  50,000  50,000 
2002  50,000  50,000 
and subs;  yrs 
Total  325,000 
8  FRAUD PREVENTION MEASURES 
The normal measures for control of expenditure, used .for meetings, will apply. 
9  ELEMENTS OF' COST-EFFECTIVENESS ANALYSIS 
9.1  Spedfic and quantified objectives; target population 
Delays in the initiation of multi centre clinical tr:ials have been identified by the 
phan;naceutical industry as well as bodies such  <'-~ the European Organisation for 
.  Research and Treatment of Cancer (EORTC). A memorandum regarding these 
delays and the disadvantages of collaborative clinical research in Europe as 
compared to the U.S. have pointed te delays of up to six months in the 
· initiation of research. 
The Industriaj Research and Dev~lopment Advisory Committee of the European 
Cmnmission -(IRDAC) has proposed that future legislation for the initial testing 
of new mediCinal products should be standardised throughout the EC- the 
establishment of a fast-acting p_rocedur~ for approving and facilitating the  . 
initiatio~ of clinical trials would make clinicalresearch more_ efficient· n Europe 
(a rough _guide to· cost of clinical research is 2.5 million ECU per month).  __ 
. The proposal also includes measures to improve both of these problems and 
aims at contributing towards ensuring a high level of health protection for 
human subjects in clinic31 trials. ~. 
· 9.2  Grounds for the operation 
This proposa) is designed to harmonise the legislative provisions relating to the 
conductofclinical trials for medidnal'products for human use. It incorporates 
-internationally establi:;he.d standards. and principles of protection for .fu.e human -
subject, streamlines the administrative procedures for initiating a clinical trial, . 
harmonises the reporting procedures for on-going safety monitoring and  -. 
· introduces surveillance measures through inspection.· 
The technical harmonisation required to achieve the Single market for  -
•  (  I 
pharmaceuticals was completed in 1992. As part of this process, clinical trials  --
whi~h have been cOnducted in accordance with Community rules do not require 
to be repeated within the Community.  · 
For the protection of European citizens who participate in clinical trials, -the 
principles of Good Clinical Practices which find their origin in: the Declaration . 
. of IJ;elsinki are a .fundamental ~equirement. The EC guidelines on Goo(i Clinical 
Practice_(GCP), adopted by the Committee for Proprietary Medicinal Products -
in July '90, was acclaimed internationally as setting· out, in a clear and concise 
manner, the ·standard for GCP. This was further evidenced by the GCP of the 
World Health Organisation which was largely based on the Community text. In 
addition, the European guideline provided the fram~wor~.for a tripartite GCP 
guideline between the EC, the USA and Japan within  t~elnternational  .. 
Conference on Harmonisation of  technical requirements for reg~stration of 
pharmaceuticals for human 1_.1se  (ICH). 
·  Re~erit reports and·corresponden~~-have highlighted real difficulties in the.area 
· of clinical development of new medicinal products particularly delays in the  · 
initiation Of IIJUlti centre clinical trials (ethics committee Opinion and competent . 
. -authority acceptance); manufacture and labelling. of investigational medicinal-
· .  products; oemonstration of compliance to GCP:  Th~se delays can 'cost industry 
up to six months delay(at an average ofl million ECUper month).  . 
9.3.  Monitoring and evaluation of the operation 
Evaluation will be by means of tracking implementation of Community 
legislation in Member States and monitoring the rate of development of new 
medicinal products. .  ·  . 
10  ADl\flNISTRATIVEExPENDITORE (SECTIONIII, PART A OF THE BUDGET) 
·Actual mobilization qf the necessary administrative re~ources will depend. on the 
Commission's  annual  decision  on' the  allocation  of  resources,  taking  into 
acc·.Junt the riumber of staff and additional amountsauthorized by the budgetary 
authority. 
,"> 
·~ 10.1  Effect on the number of posts 
Type of. post  Staff to be assigned to  Source  Duration 
managing the operation 
Permanent  Tem120ri!:Y:  Existing  Additional 
posts  .12Q.m  resources in  resources 
..  ·the DG or  -
department  .  -~ncemed  · 
..  -
Officials or  A  0.25.  Yes.  on-going 
temporary  B  ..  '-
staff  c 
Other resources 
Total 
-
· · If additi~nal resources are required, indicate the pace at· which  they  will  have· to  be 
made available. 
10.2  Overall flnancial impact of additional human resources 
No.additional staff are required. · 
10.3  Increase  in  other  administrative ·expenditure  as  a  result  of  the 
operation 
ECU 
Budget heading  Amounts  Method of calculation 
B5-3000  - Marginal  Publication already exists, additional 
·-
pages only 
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